Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › DTIL

Precision Biosciences

DTIL Rare disease Lead: Phase 1 5 Biotech Distilled articles ↓ 32 filings & releases ↓ Cash $81.7M (Sep 30, 2026) ↓ 5 verdicts ↓
Infectious DiseaseMetabolicNeurology CellGene Therapy

Market cap $296M 27.9M shares (10-Q, Oct 29, 2026) × $10.60 close Nov 6, 2026

Most recent annual filing: 2026-03-12

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. PBGENE-DMD interim2027PBGENE-DMD interim, 2027, material
  2. ELIMINATE-B2 HBV corporate update1Q 2027ELIMINATE-B2 HBV corporate update, 1Q 2027, routine
  3. DTIL 2024 Term Loan corporateJun 30, 2027DTIL 2024 Term Loan corporate, Jun 30, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Technology platforms

ARCUS

Proprietary genome editing platform using engineered nucleases; differs from other technologies in cut mechanism, smaller size, and simpler structure. Used for gene elimination (e.g., viral DNA), gene excision (removing large gene portions via two nucleases in a single AAV), and gene insertion. Focus areas include genetic and infectious diseases.

Targets: cccDNA

Discontinued (1)

Capital (as filed)

Cash
$81.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$148K Sep 30, 2026
Operating cash flow
−$15.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$81.7M cash per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Precision Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-07-17 Watch Precision BioSciences (DTIL) — Scientific Deep Dive for PBGENE-HBV, PBGENE-DMD and the ARCUS Pipeline First-ever human evidence of cccDNA elimination is compelling but the cure thesis is unproven, with no NUC-withdrawal data, an approvable competitor, and an ATM-dependent balance sheet.
  2. 2026-08-07 Watch UPDATE: Precision BioSciences (DTIL) - The Loan Nobody Noticed Term loan maturity pushed to 2029 removes a forced-financing cliff, but the cure thesis still rests on a NUC-withdrawal readout that has not begun and the ATM runway dependency is unchanged.
  3. 2026-08-24 Watch UPDATE: Precision BioSciences (DTIL) - The Needle Went In First PBGENE-DMD patient dosed on schedule retires execution risk but the AAV safety binary is now live and the HBV cure thesis still awaits NUC-withdrawal data.
  4. 2026-11-04 Watch UPDATE: Precision BioSciences (DTIL) - The ATM Woke Up ATM resumed with ~1.4M shares sold, cash burn better than modeled, but the cure thesis remains unproven and the AASLD abstract due Thursday could change the picture.
  5. 2026-11-06 Speculative buy speculative UPDATE: Precision BioSciences (DTIL) - The Abstract Landed, and So Did $125 Million Phase 1 declared successful with reproducible biopsy findings, DMD cleared first safety gate, and a $125M raise with a genuine specialist syndicate funds Phase 2 — a materially better risk/reward geometry, though no patient has yet come off NUCs.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (32)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)